With respect to other VEGFR tyrosine kinase inhibitors (TKIs), low baseline HGF level has been reported to correlate with better clinical outcomes in pazopanib-treated patients with renal cell carcinoma (RCC) or soft-tissue sarcoma28, 46. The gene discussed is HGF; the disease is hereditary clear cell renal cell carcinoma.